apl. Prof. Dr. Udo Gaipl

Medizinische Fakultät Department of Radiation Oncology

Corrigendum: Low Dose Radiation Therapy Induces Long-Lasting Reduction of Pain and Immune Modulations in the Peripheral Blood - Interim Analysis of the IMMO-LDRT01 Trial(Front. Immunol., (2021), 12, (740742), 10.3389/fimmu.2021.740742) (2022) Donaubauer AJ, Becker I, Weissmann T, Fröhlich B, Munoz LE, Gryc T, Denzler M, et al. Journal article, Erratum Radon Improves Clinical Response in an Animal Model of Rheumatoid Arthritis Accompanied by Increased Numbers of Peripheral Blood B Cells and Interleukin-5 Concentration (2022) Deloch L, Hehlgans S, Rückert M, Maier A, Hinrichs A, Flohr AS, Eckert D, et al. Journal article Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer (2022) Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, et al. Journal article Low-Dose Radiotherapy Leads to a Systemic Anti-Inflammatory Shift in the Pre-Clinical K/BxN Serum Transfer Model and Reduces Osteoarthritic Pain in Patients (2022) Weissmann T, Rückert M, Zhou J, Seeling M, Lettmaier S, Donaubauer AJ, Nimmerjahn F, et al. Journal article Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer Highlights der ASCO- und ESMO-Jahrestagungen 2021 zur Strahlentherapie von Kopf-Hals-Tumoren (2022) Hecht M, von der Grün J, Semrau S, Müller S, Weissmann T, Gaipl U, Iro H, et al. Journal article, Review article Definitive chemoradiotherapy of locally advanced head and neck cancer in combination with immune checkpoint inhibition-new concepts required (2021) Hecht M, Fietkau R, Gaipl U Journal article, Editorial Identification of an endogenous retroviral signature to predict PD-1 blockade response in advanced clear cell renal cell carcinoma: Integrated analysis of three clinical trials (2021) Zhou JG, Wang H, Ma H, Gaipl U Conference contribution Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors (2021) Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, et al. Journal article Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome (2021) Willner A, Fechner K, Agaimy A, Haller F, Eckstein M, Ott O, Putz F, et al. Journal article EARLY BLOOD CELL COUNT TEST (BCT) FOR SURVIVAL PREDICTION FOR NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB: INTEGRATED ANALYSIS OF 4 MULTICENTER CLINICAL TRIALS (2021) Zhou JG, Wong AHH, Wang H, Jin SH, Tan F, Chen YZ, He SS, et al. Conference contribution